Defining Value, Differentiation & De-Risking in a Competitive Landscape

As the IPF field advances beyond proof-of-concept and into an era of increasing mechanistic diversity, the question is no longer whether IPF drug development is viable, but what makes an asset truly investable.

With new mechanisms emerging and the bar for differentiation rising, clarity on what constitutes a compelling therapeutic story has never been more critical. This panel brings together investors, strategic pharma, and M&A leaders to define what “good” looks like, and what it doesn’t, in today’s IPF landscape.

Key Discussion Points:

• What Builds Conviction Early? What efficacy signals, durability data, mechanistic rationale, safety profile, and translational evidence are required at preclinical and early clinical stages to generate real investor confidence?
• Differentiation vs. Incrementalism? In a field moving beyond simply slowing FVC decline, what level of clinical impact, biomarker validation, or combination rationale is needed to stand out from the noise?
• De-Risking, Timing & Strategic Positioning? How do investors evaluate first-in-class versus best-in-class strategies? What role do trial design, regulatory strategy, management credibility, and partnership readiness play in investment and acquisition decisions?